Combined with the lack of systematic differences before and after therapy, our observations suggest that assessments of single AR variants may be insufficient for a causal understanding of a tumor’s sensitivity to androgen-targeting therapies even if their detection can serve as a proxy of total AR. Here, AR is linked to neoplasm.